By Steve Moore | Tuesday 21 March 2023
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Previously writing on regenerative medical device group Tissue Regenix (TRX), I noted argues distribution agreement ‘delight’. How’s that balance sheet now?. The group has now announced results for the 2022 calendar year, arguing they with it “having delivered on its strategy for growth whilst achieving strong commercial traction”. What does that actually mean financially though?
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Saturday »
Friday »
Wednesday »
Tuesday »
Saturday »
Friday »
Thursday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Sunday »
Saturday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »